Lilly beats Wall St Q3 expectations, helped by cost cuts

Reuters

Oct 23 (Reuters) - Eli Lilly and Co on Wednesdayreported better-than-expected quarterly earnings, helped by costcuts and strong growth of its drugs for depression, diabetes andcancer.

,

The Indianapolis drugmaker earned $1.20 billion, or $1.11per share, in the third quarter. That compared with $1.33billion, or $1.18 per share, in the year-earlier period, when ittook special charges related to a partnership agreement.

Excluding special items, Bristol-Myers earned $1.11 pershare. Analysts, on average, expected $1.04, according toThomson Reuters I/B/E/S.

View Comments